A Phase 1b/2, Randomized, Double-blind, Placebo-controlled, Multi-center Study of STMC-103H in Neonates and Infants at Risk for Developing Allergic Disease
Latest Information Update: 05 Jan 2024
At a glance
- Drugs STMC 103H (Primary)
- Indications Allergic asthma; Atopic dermatitis; Food hypersensitivity; Immediate hypersensitivity
- Focus Adverse reactions; Therapeutic Use
- Acronyms adored
- Sponsors Siolta Therapeutics
Most Recent Events
- 02 Jan 2024 Planned End Date changed from 1 Sep 2025 to 1 Oct 2025.
- 02 Jan 2024 Planned primary completion date changed from 1 Sep 2024 to 1 Nov 2024.
- 02 Jan 2024 Status changed from recruiting to active, no longer recruiting.